Media & Coverage
2025
ABK Biomedical Raises US$35M in Series D Financing
Read more»»
2024
Radioembolization With Imageable Glass Y90 Microspheres for Hepatocellular Carcinoma
Read More»»
Potential of Imageable Glass Y90 Microspheres for Radioembolization Among Patients With Hepatocellular Carcinoma
Read More»»
New investigational Eye90 microspheres® radioembolization therapy treats liver cancer in a first-in-human pilot trial – SIR Today Annual Meeting News
Read More»»
2023
ABK Biomedical’s Eye90 microspheres granted FDA breakthrough device designation – Mass Device
Read More»»
ABK Biomedical to begin clinical trial using Eye90 microspheres in medical treatment
Read More»»
ABK Biomedical gets FDA IDE approval for Route90 trial of Eye90 therapy
Read more»»
2022
FDA OKs ABK Biomedical’s Embolic Microspheres
Read More»»
A Better See-And-Do Technology
Read More»»
2021
ABK Biomedical begins liver tumour trial with Eye90 microspheres
Read more»»
Corporate Offices
Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
T. 902.442.4009
Orange County Office
555 Corporate Drive
Suite 105
Ladera Ranch, CA, 92694
USA
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.
Copyright 2022 - All International Rights Reserved